500355-52-2
Chemical Structure
MK-0873
- CAS No.: 500355-52-2
- Formula:C25H18N4O3
- Molecular Weight:422.44
IUPAC Name: 3-((3-(3-(cyclopropylcarbamoyl)-4-oxo-1,8-naphthyridin-1(4H)-yl)phenyl)ethynyl)pyridine 1-oxide
InChIKey: JJWKQXNHYDJXKF-UHFFFAOYSA-N
SMILES: O=C(C1=CN(C2=CC(C#CC3=C[N+]([O-])=CC=C3)=CC=C2)C4=NC=CC=C4C1=O)NC5CC5
Biological Activity: MK-0873 is a selective phosphodiesterase-4 (PDE4) inhibitor with an IC50 value of < 38 nM. MK-0873 inhibits LPS-induced TNF-α production. MK-0873 suppresses bronchoconstriction. MK-0873 is applicable to research related to chronic obstructive pulmonary disease, plaque psoriasis and asthma[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MK-0873 | 95.0% | MK-0873 is a selective phosphodiesterase-4 (PDE4) inhibitor with an IC50 value of < 38 nM. MK-0873 inhibits LPS-induced TNF-α production. MK-0873 suppresses bronchoconstriction. MK-0873 is applicable to research related to chronic obstructive pulmonary disease, plaque psoriasis and asthma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Boot JD, et al. MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers. Pulmonary pharmacology & therapeutics. 2008;21(3):573-7. [Content Brief]
- [2]. Rafael A, et al. Topical therapy for psoriasis: a promising future. Focus on JAK and phosphodiesterase-4 inhibitors. Eur J Dermatol. 2016 Jan-Feb;26(1):3-8. [Content Brief]
- [3]. Guay D, et al. Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor. Bioorganic & medicinal chemistry letters. 2008 Oct 15;18(20):5554-8. [Content Brief]
Keywords
